Actions for Endocrine therapies in breast cancer

Email RIS file
Bookmark
Report an Issue

Endocrine therapies in breast cancer / edited by Aman U. Buzdar

Published
Oxford ; New York : Oxford University Press, 2007.
Physical Description
1 online resource (viii, 120 pages) : illustrations
Additional Creators
Buzdar, Aman U.
Access Online

Availability

I Want It
I Want It

Finding items...

Series
Language Note
English.
Contents
Selection of patients for endocrine therapies / W. Fraser Symmans and Lajos Pusztai -- Ovarian ablation / Kellie l. Jones -- Antioestrogens / John F. Forbes -- Aromatase inhibitors in early and advanced disease / Laura Boehnke Michaud -- Fulvestrant in metastatic disease / Amit Agrawal, J.F.R. Robertson, and K.L. Cheung -- Progestins and androgens / Janet l. Espirito -- Combined endocrine and chemotherapy in breast cancer / Ishmael Jaiyesimi [and others] -- Hormone replacement therapy in patients with a prior history of breast cancer / Gilbert G. Fareau and Rena Vassilopoulou-Sellin -- Chemoprevention / Saheenah Dawood and Jack Cuzick.
Summary
Breast cancer is one of the leading causes of cancer mortality in women worldwide, and the risk of disease recurrence continues despite improvements in screening and treatment. For patients with hormone receptor-positive breast cancer, some form of endocrine therapy is central to the management of their disease. Tamoxifen has long been the mainstay of endocrine therapy in this group of patients. However, there is mounting evidence showing that the aromatase inhibitors are able toreduce overall oestrogen levels and appear to be better tolerated over a long term than tamoxifen. New and emerging.
Subject(s)
ISBN
9780191575174 (electronic bk.)
0191575178 (electronic bk.)
9780199218141
0199218145
0191739871
9780191739873
0199606994
9780199606993
1283580756
9781283580755
9786613893208
661389320X
Bibliography Note
Includes bibliographical references and index.
View MARC record | catkey: 43171967